LBRX

20.73

0.34% -0.07

Handel nachbörslich: 20.65 -0.08 -0.39%

Lb Pharmaceuticals Inc (LBRX)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$20.80

Offen:

$21.16

24-Stunden-Volumen:

213.53K

Relative Volume:

0.85

Marktkapitalisierung:

$524.45M

Einnahmen:

Nettoeinkommen (Verlust:

KGV:

EPS:

Netto-Cashflow:

1W Leistung:

+1.42%

1M Leistung:

-5.69%

6M Leistung:

+0.00%

1J Leistung:

+0.00%

1-Tages-Spanne:

$20.21

$21.43

1-Wochen-Bereich:

$19.38

$21.52

52-Wochen-Spanne:

$13.36

$23.15

Lb Pharmaceuticals Inc Stock (LBRX) Company Profile

Firmenname

Lb Pharmaceuticals Inc

Sektor

Healthcare (1115)

Branche

Biotechnology (621)

Telefon

917-450-6581

Adresse

575 MADISON AVENUE, NEW YORK

Mitarbeiter

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

LBRX's Discussions on Twitter

Vergleichen Sie LBRX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
LBRX Lb Pharmaceuticals Inc	20.73	526.22M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	463.86	119.17B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	796.55	84.19B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	398.29	52.77B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	788.49	48.98B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.97	36.31B	447.02M	-1.18B	-906.14M	-6.1812

Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-09	Eingeleitet	Roth Capital	Buy
2025-10-06	Eingeleitet	Leerink Partners	Outperform
2025-10-06	Eingeleitet	Piper Sandler	Overweight
2025-10-06	Eingeleitet	Stifel	Buy

Lb Pharmaceuticals Inc Aktie (LBRX) Neueste Nachrichten

06:01 AM

LB Pharmaceuticals (NASDAQ:LBRX) Stock Rating Upgraded by Roth Capital - MarketBeat

06:01 AM

Jan 09, 2026

Roth/MKM initiates LB Pharmaceuticals stock with Buy rating on schizophrenia drug potential - Investing.com

Jan 09, 2026

Roth/MKM initiates LB Pharmaceuticals stock with Buy rating on schizophrenia drug potential By Investing.com - Investing.com Canada

Jan 09, 2026

Jan 08, 2026

PR News | On the Move: The Trevor Projects Names Wong CCOThu., Jan. 8, 2026 - O'Dwyer's PR

Jan 08, 2026

Poplar’s $50 million Series A to ‘transform treatment of atopic diseases’ - The Pharma Letter

Jan 08, 2026

Jan 06, 2026

LB Pharmaceuticals Appoints Ellen Rose and Lindsay Beaupre as Senior Vice Presidents - citybiz

Jan 06, 2026

LB Pharmaceuticals appoints two executives to leadership team By Investing.com - Investing.com Canada

Jan 06, 2026

LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture - The Manila Times

Jan 06, 2026

Jan 05, 2026

Stifel maintains LB Pharmaceuticals (LBRX) buy recommendation - MSN

Jan 05, 2026

Jan 04, 2026

Schizophrenia drug developer LB Pharma jumps in trading debut - MSN

Jan 04, 2026

Jan 02, 2026

LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Down 7.7%Should You Sell? - MarketBeat

Jan 02, 2026

Dec 31, 2025

LB Pharmaceuticals (NASDAQ:LBRX) Trading Up 3.8%Here's Why - MarketBeat

Dec 31, 2025

Dec 23, 2025

Top financings 2025 - BioWorld MedTech

Dec 23, 2025

LB Pharmaceuticals Inc (NASDAQ:LBRX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Dec 23, 2025

Dec 21, 2025

LB Pharmaceuticals Inc(NasdaqGM: LBRX) added to S&P TMI Index - marketscreener.com

Dec 21, 2025

Dec 19, 2025

Aktis Oncology files for US IPO as biotech listings rebound - 1470 & 100.3 WMBD

Dec 19, 2025

Pai Panandiker Kaya Kamlesh Net Worth (2025) - GuruFocus

Dec 19, 2025

Dec 18, 2025

LB Pharmaceuticals Inc(NasdaqGM: LBRX) added to Russell 3000 Index - marketscreener.com

Dec 18, 2025

LB Pharmaceuticals Inc(NasdaqGM: LBRX) added to Russell 3000E Index - MarketScreener

Dec 18, 2025

Dec 15, 2025

LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat

Dec 11, 2025

Lexicon publishes preclinical data validating ACSL5 as obesity target By Investing.com - Investing.com Nigeria

Dec 11, 2025

Dec 10, 2025

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Dec 10, 2025

LB Pharmaceuticals (Nasdaq: LBRX) issues inducement equity grant to incoming CCO - Stock Titan

Dec 10, 2025

LB Pharmaceuticals (LBRX) Stock Analysis Report | Financials & Insights - Benzinga

Dec 10, 2025

Lexicon publishes preclinical data validating ACSL5 as obesity target - Investing.com

Dec 10, 2025

LB Pharmaceuticals Added to the Russell 2000 and Russell 3000 Indices - marketscreener.com

Dec 10, 2025

Dec 09, 2025

LB Pharmaceuticals (NASDAQ:LBRX) Trading Down 4.8%Here's Why - MarketBeat

Dec 09, 2025

LB Pharmaceuticals Added to Russell 2000, 3000 Indices - marketscreener.com

Dec 09, 2025

LB Pharmaceuticals to join Russell 2000 and Russell 3000 indices - Investing.com

Dec 09, 2025

LB Pharmaceuticals to join Russell 2000 and Russell 3000 indices By Investing.com - Investing.com Canada

Dec 09, 2025

LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices - marketscreener.com

Dec 09, 2025

Dec 08, 2025

LB Pharmaceuticals (NASDAQ:LBRX) Trading Up 6.2%Still a Buy? - MarketBeat

Dec 08, 2025

Dec 06, 2025

LB Pharmaceuticals (NASDAQ:LBRX) Hits New 52-Week HighHere's What Happened - MarketBeat

Dec 06, 2025

Dec 03, 2025

LBRX: $300M IPO funds phase III schizophrenia and phase II bipolar depression trials, with 2027 data expected - TradingView

Dec 03, 2025